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Abstract. We describe the case of a 17
syndrome (HPS) one month following acute infection caused by Epstein
initiation of treatment and reduction of EBV load, laboratory signs of HPS as severe cytopenia, 
hypofibrinogenemia, hyperferritinemia and hypertriglyceridemia p
multiorgan failure. HPS is a rare, but life
Introduction. The haemophagocytic syndrome (HPS) 
represents a severe and aggressive hyperinflammatory 
disease  with  major  diagnostic  and  therapeutic 
difficulties.
1-3 HPS  is  a  spectrum  of  inherited  and 
acquired conditions with disturbed immune regulation 
which  results  into  a  dysregulated  ac
proliferation  of  lymphocytes.  Haemophagocytosis  is 
part  of  a  sepsis-like  syndrome  caused  by  severe 
hypercytokinemia as result of a highly stimulated but 
ineffective immune response.  Cardinal symptoms are 
prolonged  fever,  cytopenia  affecting  a
three lineages, hepatosplenomegaly and coagulopathy 
with  hypofibrinogenemia.  Diagnostic  criteria  for  this 
disorder are shown in Table 1 edited by the Histiocyte 
Society.
2  
HPS may be the consequence of a familial immune 
dysregulatory disorder or be associated with a number 
of  different  infections,  autoimmune  disorders  or 
malignancies,  like  lymphomas  or  carcinomas
Frequent triggers are infectious agents, especially virus 
of  the  herpes  group.
6    Among  the  infectious  agents 
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We describe the case of a 17- year old female who developed  fatal  haemophagocytic
syndrome (HPS) one month following acute infection caused by Epstein-Barr virus (EBV). Despite 
initiation of treatment and reduction of EBV load, laboratory signs of HPS as severe cytopenia, 
hypofibrinogenemia, hyperferritinemia and hypertriglyceridemia persisted, and the patient died of 
multiorgan failure. HPS is a rare, but life-threatening complication of EBV infection. 
syndrome (HPS) 
represents a severe and aggressive hyperinflammatory 
disease  with  major  diagnostic  and  therapeutic 
HPS  is  a  spectrum  of  inherited  and 
acquired conditions with disturbed immune regulation 
which  results  into  a  dysregulated  activation  and 
proliferation  of  lymphocytes.  Haemophagocytosis  is 
like  syndrome  caused  by  severe 
hypercytokinemia as result of a highly stimulated but 
ineffective immune response.  Cardinal symptoms are 
prolonged  fever,  cytopenia  affecting  at  least  two  of 
three lineages, hepatosplenomegaly and coagulopathy 
with  hypofibrinogenemia.  Diagnostic  criteria  for  this 
edited by the Histiocyte 
HPS may be the consequence of a familial immune 
er or be associated with a number 
of  different  infections,  autoimmune  disorders  or 
malignancies,  like  lymphomas  or  carcinomas.
4,5
Frequent triggers are infectious agents, especially virus 
Among  the  infectious  agents 
associated with HPS there are EBV, Cytomegalovirus, 
Parvovirus, Varicella zoster, Herpes
Herpes-Virus  8  and  HIV  infection  alone  or  in 
combination.  EBV  is  the  most  common  infectious 
agent.
EBV-associated haemophagocytic syndrome has a 
relatively  high  incidence  in  Asian  countries  and 
particularly in Japan.
3 Here we present a case of EBV
associated  haemophagocytic  syndrome  in  a  young 
Italian women that was fatal despite prompt medical 
treatment.
Case Presentation. A 17 year
admitted  to  our  hospital  for  fever,  fatigue  and 
abdominal discomfort. Her medical history showed no 
relevant  data;  in  particular  no  recurrent  infectious 
episodes  were  documented  except  for  the  common 
childhood diseases. One month before the admission, 
the  patient  suffered  from  infectious  mononucleosis. 
She  had  developed  a  widespread  skin  rash  during 
antibiotic therapy with amoxicillin given for fever. 
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year old female who developed  fatal  haemophagocytic
Barr virus (EBV). Despite 
initiation of treatment and reduction of EBV load, laboratory signs of HPS as severe cytopenia, 
ersisted, and the patient died of 
threatening complication of EBV infection. 
PS there are EBV, Cytomegalovirus, 
Parvovirus, Varicella zoster, Herpes-simplex as well as 
Virus  8  and  HIV  infection  alone  or  in 
combination.  EBV  is  the  most  common  infectious 
associated haemophagocytic syndrome has a 
dence  in  Asian  countries  and 
Here we present a case of EBV-
associated  haemophagocytic  syndrome  in  a  young 
Italian women that was fatal despite prompt medical 
A 17 year-old white woman was 
ur  hospital  for  fever,  fatigue  and 
Her medical history showed no 
relevant  data;  in  particular  no  recurrent  infectious 
episodes  were  documented  except  for  the  common 
One month before the admission, 
the  patient  suffered  from  infectious  mononucleosis. 
She  had  developed  a  widespread  skin  rash  during 
antibiotic therapy with amoxicillin given for fever. AMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 1: Diagnostic criteria for HPS: One of two criteria should be present for correct diagnosis
4
1) Molecular diagnosis of familial haemophagocytosis (Pathologic mutations of Perforin (PRF1), SH2D1A/SAP, UNC13D, Syntaxin
11 (STX11), MUNC18-2, Ras-related Protein Rab27a (RAB27a))
Or 
2) Five out of eight diagnostic criteria listed below are fulfilled:
1. Fever ≥38.5°C
2. Splenomegaly
3. Cytopenias (affecting at least 2 of 3 lineages in the peripheral blood):
Hemoglobin <9 g/dl (in infants <4 weeks: hemoglobin <10 g/dl)
Platelets <100X103/ml
Neutrophils <1X103/ml
4. Hypertriglyceridemia (fasting, > 265 mg/dl) and/or hypofibrinogenemia (<150 mg/dl)
5. Hemophagocytosis in bone marrow or spleen or lymph nodes or liver
6. Low or absent NK-cell activity
7. Ferritin > 500 ng/ml
8. Elevated Soluble CD25 (alpha chain of soluble IL-2 receptor)
that time, the monospot test resulted positive and the 
patient  received  corticosteroids  with  symptoms 
improvement.  
On  admission,  the  physical  examination  showed 
splenomegaly  without  palpable  lymphadenopathy. 
Laboratory evaluation revealed a severe pancytopenia: 
platelet count was 17x 10
6/mmc, hemoglobin was 7,2 
g/dl  and  she  had  a  leucocyte  count  of  230/mmc.  
Lactate dehydrogenase was strongly increased to 1570 
UI/l,  while  GPT  was  217 U/l  and  bilirubin was
Table 2.  Laboratory data of the patient
Complete blood cell counts Normal range
GB 0.23 X 10
9/l 4-10 X 10
9/l
Platelets 17  X 10
9/l 150-450 X 10
9/l
Hemoglobin 7,2 g/dl 12-14 g/dl
Biochemistry
LDH 1570 UI/l 230-460 UI/l
GPT 217 UI/l 7-45 UI/l
Creatinina 0,9 mg/dl 7-1,2 mg/dl
BUN 18 mg/dl 10-23 mg/dl
Bilirubin 4.6 mg/dl 0.3-1.2 mg/dl
Ferritin 6421 ng/ml 11-307 ng/ml
Coagulation tests
PT 10,2 sec.
Fibrinogen 43 mg/dl 200-400 mg/dl
INR 0,97 0,8-1,2
Immunological tests
IgG 903 mg/dl 700-1600 mg/dl
IgM 96 mg/dl 40-230 mg/dl
IgD 119 U/ml <110 U/ml
IgE 37 UI/ml <100 UI/ml
IgA 154 mg/dl 70-400 mg/dl
elevated to 4,6mg/dl (Table 2). Clotting tests showed 
severe  hypofibrinogenemia  with  a  normal  value  of 
international normalized ratio (INR) and of activated 
partial  thromboplastin  time  (aPTT).  A  bone  marrow 
aspiration  for  the  suspect  of  an  acute  hematological 
proliferative  disease  was performed,  but  was  not 
diagnostic.  Ferritin  levels  were  high  (6421  ng/ml). 
Serological  studies  for  HIV  1,2,  hepatitis  B  and  C, 
cytomegalovirus, parvovirus were negative. Both IgG 
and  IgM  anti- viral  capsid  antigen  (VCA) EBV 
antibodies  were  positive,  while anti-EBV  nuclear 
antigen  were  negative,  indicating  a  recent  primary 
EBV  infection. Amplification  of  EBV-DNA  from 
whole  blood  by  polymerase  chain  reaction  (PCR) 
yielded 930.000 copies/ml.  As the patient presented 
signs  of  an  acute  colecystitis,  she  was  treated  with 
trans-hepatic drainage of the gall-bladder. 
Acute  acalcolous  colecystitis  (AAC)  observed  in 
our patient, reflected the severe  inflammatory response 
associated  with  the  primary  EBV  infection.    In 
addition, the bile stasis can also been implicated in the 
gallbladder inflammation pathogenesis. Moreover, also 
EBV-induced  hepatitis  has  been  recognized  as  an 
important  cause  of  cholestasis.  Finally,  another 
possible  pathogenetic  mechanism,  may  be  the  direct 
invasion of the gallbladder  from the EBV-virus. AAC 
may develop during the course of acute EBV infection, 
especially in patients with cholestatic  hepatitis.
6,7  
Clinical  conditions  of  our  patient  rapidly
deteriorated  and  she    was    transferred  to  the
Table 3. Bone marrow cytology.
Myelogram 
- Erytroid lineage                    4%
- Granulocytic lineage         35%
- Lymphocytes                       54%
- Eosinophils                           2%
- Monocytes                           5%
Comment. Several  histiocytes  with  signs  of  phagocytosis of 
erythrocytes and plateletsMediterr J Hematol Infect Dis 2012; 4: Open Journal System
            
Figure 1. A) Giemsa staining of the bone marrow biopsy. Morphological signs of hemophagocytosis with numerous macrophages engulfing 
various cellular elements in their cytoplasm. B) Immunohistochemical analysis for CD68 in the bone marrow biopsy utilizing the PGM-1 
antibody. 
intensive  care  unit  on  day  2  following  admission.  
Hemophagocytic syndrome  was  suspected  and 
confirmed  by  a  second  bone  marrow  examination 
(Table  3).  Bone  marrow  cytology  and  histology 
revealed  several  histiocytes  with  phagocytosis  of 
erythrocytes  and  platelets  (Figure  1).  The  bone 
marrow biopsy showed phagocytic cells with engulfed 
haemopoietic elements.  The presence of large sized T 
lymphocytes  in  the  biopsy  raised  the  suspicion  of 
EBV-related T-lymphoproliferative disease.
The patient was immediately started on high doses 
of corticosteroids and immunoglobulins  (1g/kg for two 
days).  As  the  clinical  conditions  did  not  improve, 
treatment with etoposide was started according to the 
HLH-94  protocol.  Etoposide  was  administered  in  a 
dose of 150 mg/m 
2, on day 9 and day 12. EBV copy 
numbers  slowly  decreased,  and  laboratory  signs  of 
HPS  as  severe  hypofibrinogenemia  and 
hyperferrtinemia  improved  (Figure  2),  but 
pancytopenia persisted and the patient was supported 
with  massive  transfusions  of  blood  and  fresh  frozen 
plasma,  granulocyte-colony  stimulating  factor  (G-
CSF), and antibiotics.  The patient died in multiorgan 
failure on day 15 following admission.
Discussion. Haemophagocytic syndrome (HPS) is the 
most severe complication of infectious mononucleosis. 
HPS is a highly fatal disease if untreated or treated late. 
Diagnosing HPS  is  a challenge, as  there is no single 
simple  diagnostic  test,  and    it  remains  a  syndromic 
disorder with a combination of typical findings being 
often initially absent but developing with progressive 
disease.  Because of diagnostic difficulties, diagnosis 
of HPS is often delayed and only established when the 
patient  is  already  critically  ill  and  transferred  to  the 
intensive care unit, as in our case. 
As  EBV  responds  poorly  to  antiviral  agents, 
treatment  is  aimed  at  controlling  the 
lymphocyte/macrophage  activation  and  proliferation. 
In  addition  to  corticosteroids  and  immunoglobulins, 
treatment  of  EBV-associated  HPS  often  requires 
administration  of  etoposide.
8,9 Repetitive 
administration  of  a  myelosuppressive  agent  in  an 
already severe cytopenic patient with a high risk for 
additional infectious complications is not  trivial, and 
should be limited to centers experienced in treatment of 
acute haematological diseases.  
Since  HPS  is  rare,  no  data  are  available  from 
randomized  controlled  clinical  trials  testing  potential 
different treatment approaches. As T cell dysregulation 
appears  to  be  involved  in  the  pathogenesis  of  both 
primary  and  secondary  HPS,  treatment  with  anti-
thymocyte  globulins  (ATG)  has  been  reported  as  an 
alternative to etoposide-based therapy in a single center 
study on patients with familial  HPS.
10  An on-going 
trial of the Histiocyte Society studies the early addition 
of cyclosporine to the etoposide-based regimen.
11 An 
additional therapy for patients with progressive EBV-
associated HPS may be rituximab, at it can eliminate 
EBV-infected B cells.
12 
Bone marrow histology raised the suspicion of a T 
cell  lymphoma  in  our  patient.  Lymphomas  of  T-cell 
and  NK-cell  origin  are  among  the  most  common 
neoplasias  associated  with  secondary  malignancy-
associated  HPS.
4,5,11 This  association  has  been  more 
frequently been reported in Asian countries where the 
incidence of EBV-associated lymphomas appear to be 
significantly  higher.  In  fact  some  studies  describe 
fulminant  EBV-T  cell  lymphoproliferative  disorders 
following  acute  EBV-infection.
13    However,  the 
suspicion in our patient was not substantiated by other 
signs  of  a  lymphoproliferative  disease,  although  we 
cannot  rule  out  that  the  EBV-induced 
lymphoproliferation  in  our  patient  was  already 
indication of transformation into a malignant disease.  
In  this  case,  only  the  assessment  of  the  monoclonal 
nature  of  the  EBV-infected  T  cell  expansion  could 
have  definitely  indicate  the  transformation  in
A BMediterr J Hematol Infect Dis 2012; 4: Open Journal System
       
Figure  2.  Changes  in  laboratory  parameters  during  the  clinical  course  of  the  patient.  The  blue  arrays  indicate  the  administration  of 
immunoglobulins (1 g/kg) on days 4 and 5, the red arrows indicate therapy with etoposide (150 mg/m
2).
lymphoma.
In  conclusion,  our  case  highlights  that 
hemophagocytic syndrome can complicate acute EBV-
infection, and should raise the awareness for this rare 
life-threatening  syndrome  in  order  to  promptly  start 
appropriate treatment. 
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